Online citations, reference lists, and bibliographies.

Product Innovation Success Based On Cancer Research In The Pharmaceutical Industry: Co-publication Networks And The Effects Of Partners

Maureen Mckelvey, Bastian Rake
Published 2016 · Economics

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract This paper builds upon the literature which provides conflicting theoretical insights and empirical results concerning the importance of companies’ collaborative relations, their position within a network of collaborative relations and the effects on their innovative performance. Taking the importance of collaborations and networks in the pharmaceutical industry into account, the paper untangles the influence of the firm’s co-publication relations with different types of partners and its network position on the company’s product innovation in a specific disease area—cancer. We find rather robust evidence that in particular, companies’ indirect connections within the co-publication network, including connections to academic institutions and biotechnology companies, support product innovation. In contrast to evidence in the strategic alliance literature, direct co-publication links to biotechnology companies do not support product innovation in terms of new cancer medications.
This paper references
10.1257/000282802760015649
When Do Research Consortia Work Well and Why? Evidence from Japanese Panel Data
L. Branstetter (2000)
THE BEST OF BOTH WORLDS: THE BENEFITS OF SPECIALIZED-BROKERED AND DIVERSE-CLOSED SYNDICATION NETWORKS FOR NEW VENTURE SUCCESS (SUMMARY)
A. T. Wal (2013)
10.1086/210179
Where Do Interorganizational Networks Come From
Ranjay Gulati (1999)
10.1007/S00168-008-0252-9
The geography of collaborative knowledge production in Europe
J. Hoekman (2009)
10.1086/421508
Network dynamics and field evolution : The growth of interorganizational collaboration in the life sciences
W. Powell (2005)
10.5860/choice.40-4732
The Gifts Of Athena Historical Origins Of The Knowledge Economy
K. Kaiser (2016)
10.2307/2393143
An Evolutionary Theory of Economic Change.
J. Barney (1982)
The Evolution of Pharmaceutical Innovation.
P. Nightingale (2006)
10.1086/228631
Power and Centrality: A Family of Measures
P. Bonacich (1987)
Knowledge Flows within Multinational
L. F. Press. Monteiro (2008)
10.1016/J.RESPOL.2006.01.006
Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks
N. Roijakkers (2006)
10.2307/3033543
A set of measures of centrality based upon betweenness
L. Freeman (1977)
10.1016/J.JBUSVENT.2013.11.001
When do firms benefit from university–industry R&D collaborations? The implications of firm R&D focus on scientific research and technological recombination
Pek-Hooi Soh (2014)
10.2307/3556658
Network Structure and Knowledge Transfer: The Effects of Cohesion and Range
Ray Reagans (2003)
10.1093/icc/5.1.51
The Dynamics and Evolution of Industries
F. Malerba (1996)
10.1038/nrd1470
Can the pharmaceutical industry reduce attrition rates?
I. Kola (2004)
10.1016/j.socnet.2007.04.002
Some unique properties of eigenvector centrality
Phillip Bonacich (2007)
The Quantity and Quality of Worldwide New Drug
IndusTRy (2006)
10.2139/ssrn.1860026
Determinants of Alliance Portfolio Complexity and its Effect on Innovative Performance of Companies
G. Duysters (2008)
The Geography of Collaborative Knowledge
J. Hoekman (2009)
10.2307/2067047
Communication Networks: Toward a New Paradigm for Research
E. Rogers (1980)
10.1111/J.1467-9310.2005.00383.X
Indirect Networks: An Intangible Resource for Biotechnology Innovation
Nader Salman (2005)
10.2139/ssrn.2533187
Understanding the Alliance Data
Melissa A. Schilling (2008)
10.4337/9781845420611
The economic dynamics of modern biotechnology
Maureen Mckelvey (2004)
10.2307/1057761
"Innovation in the Pharmaceutical Industry".
D. Schwartzman (1978)
10.1016/j.techfore.2012.06.007
Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline
I. Rafols (2013)
10.1016/0304-4076(90)90014-K
Regression-based tests for overdispersion in the Poisson model
A. Cameron (1990)
10.1038/nrd2961
Lessons from 60 years of pharmaceutical innovation
B. Munos (2009)
10.1017/CBO9780511493270.004
Pharmaceuticals Analyzed through the Lens of a Sectoral Innovation System
Maureen Mckelvey (2004)
A Cognitive Theory of the Firm: Learning, Governance and Dynamic Capabilities
B. Nooteboom (2009)
10.1001/jama.1996.03530250077035
Science and Innovation: The US Pharmaceutical Industry During the 1980s
B. Spilker (1996)
10.1016/S0048-7333(99)00003-7
Innovative output, and a firm's propensity to patent.: an exploration of CIS micro data
E. Brouwer (1999)
10.1016/0378-8733(78)90021-7
Centrality in social networks conceptual clarification
L. Freeman (1978)
10.2307/3107066
Evolutionary Innovations: The Business of Biotechnology
Maureen Mckelvey (1996)
Microeconometrics Using Stata
A. C. Cameron (2009)
10.1016/S0024-6301(99)00117-X
Strategies for Managing Knowledge Assets: the Role of Firm Structure and Industrial Context
D. Teece (2000)
10.1023/A:1011489124123
Where Science Comes to Life: University Bioscience, Commercial Spin-offs, and Regional Economic Development
M. Feldman (2000)
Can science be a business? Lessons from biotech.
G. Pisano (2006)
10.1257/00028280260344704
R&D Cooperation and Spillovers: Some Empirical Evidence from Belgium
B. Cassiman (2002)
10.1016/S0048-7333(99)00030-X
An Analysis of the Critical Role of Public Science in Innovation: The Case of Biotechnology
G. McMillan (2000)
10.1287/mnsc.48.1.24.14275
Special Issue on University Entrepreneurship and Technology Transfer: A Comparison of U.S. and European University-Industry Relations in the Life Sciences
Jason Owen-Smith (2002)
10.1111/J.0737-6782.2005.00120.X
Interorganizational collaboration and innovation: Toward a portfolio approach
D. Faems (2005)
10.1093/OXFORDHB/9780199286805.003.0003
Networks of Innovators
W. Powell (2006)
Network Position and Firm Performance: Organizational Returns to Collaboration in the Biotechnology Industry
W. Powell (1999)
10.2307/3094892
Network Learning: The Effects of Partners' Heterogeneity of Experience on Corporate Acquisitions
Christine M. Beckman (2002)
10.1016/S0048-7333(00)00142-6
Complementary Assets, Strategic Alliances, and the Incumbent's Advantage: An Empirical Study of Industry and Firm Effects in the Biopharmaceutical Industry
F. Rothaermel (2001)
10.1017/CBO9780511753978.002
Investigating causal relations by econometric models and cross-spectral methods
C. Granger (2001)
10.1177/0149206311432640
Knowledge, Networks, and Knowledge Networks: A Review and Research Agenda
C. Phelps (2011)
10.1016/0048-7333(94)01003-X
The changing technology of technological change: general and abstract knowledge and the division of
A. Arora (1994)
10.1016/S0048-7333(00)00094-9
Technological change and network dynamics: Lessons from the pharmaceutical industry
L. Orsenigo (2001)
10.2307/2667105
Collaboration Networks, Structural Holes, and Innovation: A Longitudinal Study
G. Ahuja (2000)
10.1287/orsc.13.3.232.2771
Special Issue: Knowledge, Knowing, and Organizations: Knowledge Networks: Explaining Effective Knowledge Sharing in Multiunit Companies
Morten T. Hansen (2002)
The Economic Dynamics of Modern Biotechnology, Edward Elgar, Cheltenham.
T. McKelvey (2004)
10.1287/ORSC.2013.0856
Going Underground: Bootlegging and Individual Innovative Performance
P. Criscuolo (2014)
10.1002/smj.4250171110
Toward a Knowledge-Based Theory of the Firm,” Strategic Management Journal (17), pp.
Rm Grant (1996)
10.1016/S0048-7333(02)00070-7
Innovation as co-evolution of scientific and technological networks: exploring tissue engineering
F. Murray (2002)
Competitive cooperation in biotechnology: Learning through networks?" In N
W. Powell (1992)
10.1016/J.RESPOL.2003.07.003
R&D cooperation and innovation activities of firms—evidence for the German manufacturing industry
W. Becker (2004)
10.1016/J.RESPOL.2007.02.013
The myth of the biotech revolution: An assessment of technological, clinical and organisational change
M. Hopkins (2007)
Production in Europe.
M. M. Hopkins (2007)
10.2139/ssrn.265999
R&D Alliances & Firm Performance: The Impact of Technological Diversity and Alliance Organization on Innovation
R. Sampson (2001)
10.1093/ICC/9.1.1
A firm as a knowledge-creating entity: a new perspective on the theory of the firm
I. Nonaka (2000)
10.1017/CBO9780511493232
Knowledge accumulation and industry evolution: the case of Pharma-Biotech
M. Mazzucato (2006)
10.1073/pnas.93.23.12725
Public-private interaction in pharmaceutical research.
I. Cockburn (1996)
10.1080/0022250X.1972.9989806
Factoring and weighting approaches to status scores and clique identification
Phillip Bonacich (1972)
10.1287/orsc.3.3.383
Knowledge of the Firm, Combinative Capabilities, and the Replication of Technology
B. Kogut (1992)
10.1016/0048-7333(91)90077-4
Informal Technology Transfer Between Firms: Cooperation Through Information Trading
S. Schrader (2015)
10.4337/9781848447424
A Cognitive Theory of the Firm
B. Nooteboom (2005)
10.1287/orsc.1070.0264
Knowledge Flows Within Multinational Corporations: Explaining Subsidiary Isolation and Its Performance Implications
L. F. Monteiro (2008)
10.1080/713698467
Technological Discontinuities and the Nature of Competition
F. Rothaermel (2000)
10.5465/ambpp.1993.10317102
INTERFIRM COOPERATION AND STARTUP INNOVATION IN THE BIOTECHNOLOGY INDUSTRY.
G. Walker (1993)
Comprar Drug Information Handbook, 18th | Leonard L. Lance | 9781591952541 | Lexi-Comp Inc
L. Lance (2009)
10.1007/bf01322868
Business cycles
G. Briefs (1949)
10.1002/JAE.992
The Relationship between R&D Collaboration, Subsidies and R&D Performance: Empirical Evidence from Finland and Germany
D. Czarnitzki (2007)
The Make or Cooperate Decision in the Context of an Industry Network
B Kogut (1992)
10.1016/J.JBUSRES.2013.12.005
Returns to alliance portfolio diversity : The relative effects of partner diversity on firm’s innovative performance and productivity
Tim de Leeuw (2014)
10.2189/asqu.2009.54.1.90
Networks, Propinquity, and Innovation in Knowledge-intensive Industries
Kjersten Bunker Whittington (2009)
10.1287/orsc.1030.0054
Knowledge Networks as Channels and Conduits: The Effects of Spillovers in the Boston Biotechnology Community
Jason Owen-Smith (2004)
10.1007/978-3-540-47648-1_3107
International Agency for Research on Cancer.
H. Bartsch (1969)
10.1007/S00191-007-0059-3
Endogenous innovations in the pharmaceutical industry
R. Cerda (2007)
10.1111/1467-6451.00067
Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery
Iain M. Cockburn (2003)
10.1257/jep.5.1.29
Standing on the Shoulders of Giants: Cumulative Research and the Patent Law
S. Scotchmer (1991)
10.4337/9781848449275.00011
Measuring the Corporate Web of Science: Research and Partnership Networks within the European Pharmaceutical Industry
Robert J. W. Tijssen (2009)
Statistical Definition of Biotechnology
(2005)
10.1016/J.RESPOL.2007.12.011
A neo-Schumpeterian model of health services innovation
P. Windrum (2008)
10.5465/AMJ.2010.52814627
A Longitudinal Study of the Influence of Alliance Network Structure and Composition on Firm Exploratory Innovation
C. Phelps (2009)
Pharmaceuticals Analyzed through the Lens
M. Press. McKelvey (2004)
The Best of Both Worlds: The Benefits of Specialized-brokered and Diverse-closed Syndication Networks for New Venture Success.” Paper Presented at the 35th DRUID Celebration
A. Ter Wal (2013)
10.1177/0170840602234002
Learning in Dynamic Inter-Firm Networks: The Efficacy of Multiple Contacts
J. Hagedoorn (1999)
The best of both worlds : The benefits of specialized-brokered and diverse-closed syndication networks for new venture success
A. T. Wal (2013)
10.2307/2393988
Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology.
W. Powell (1996)
10.1016/S0883-9026(01)00069-6
The effects of business-university alliances on innovative output and financial performance: a study of publicly traded biotechnology companies
G. George (2002)
10.1377/HLTHAFF.25.2.452
The quantity and quality of worldwide new drug introductions, 1982-2003.
H. Grabowski (2006)
10.4324/9780203265277
Inter-firm alliances: Analysis and design
B. Nooteboom (1999)



This paper is referenced by
Use me when you need me : firms ’ co-creation output with universities , scientific impact and the economic cycle
Ana María Castellanos Gómez (2019)
Taking a step into the unknown : The guiding role of collaboration partners in firms ' entry into new research areas
L. Colen (2019)
10.1080/19420862.2017.1356527
Evolving patterns in a collaboration network of global R&D on monoclonal antibodies
Xiangjun Kong (2017)
10.1007/s11192-020-03344-5
Exploring scientific publications by firms: what are the roles of academic and corporate partners for publications in high reputation or high impact journals?
Maureen Mckelvey (2020)
10.1080/13662716.2017.1343132
Linking content and technology: on the geography of innovation networks in the Bergen media cluster
R. Martin (2018)
10.1155/2019/9241817
The Intertemporal Evolution Model of Enterprise R&D Cooperative Network
Rongguo Qiu (2019)
10.1080/14479338.2019.1679024
Do publication activities of academic institutions benefit from formal collaborations with firms
Bastian Rake (2019)
10.1016/J.TECHFORE.2018.10.025
University-industry scientific production and the Great Recession
Joaquín M. Azagra-Caro (2019)
10.7166/30-2-1977
MEDICAL DEVICE INNOVATION IN SOUTH AFRICA: EVOLUTION OF COLLABORATION NETWORKS (2001-2013)
Kylie de Jager (2019)
10.1108/IJM-02-2018-0078
Dimensions of organisational innovativeness and company financial performance in the biotechnology sector
K. Jaakson (2019)
10.1108/S0573-855520180000294010
R&D Success in Pharmaceutical Markets: A Duration Model Approach
Eliana Barrenho (2018)
10.24265/campus.2019.v24n28.05
Productividad científica profesional mediante indicadores de reconocimiento o visibilidad y de pertenencia repulsiva
George Argota Pérez (2019)
Semantic Scholar Logo Some data provided by SemanticScholar